Collection of Blood, Bone Marrow, Urine, and/or Tissue Samples From Patients With Solid Tumors, Hematological Malignancies or Non-Malignant Hematologic Disorders or HLA Compatible Family Members
The purpose of this protocol is to collect blood, bone marrow, urine, stool, buccal mucosa
and/or both malignant and non-malignant tissue from patients who are either being evaluated
for enrollment, are consented to NIH Clinical Center treatment protocols, or are receiving
therapy for their disease through home health care providers. Since a substantial
proportion of the clinical and translational research in the Hematology Branch involves
patients undergoing allogeneic stem cell transplantation, this protocol will also be open to
people identified as suitable HLA-compatible donors for patients undergoing evaluation for
or already enrolled in an allogeneic stem cell transplant protocol or receiving a stem cell
transplant through their home health care providers. These HLA-compatible donors will serve
as a source of peripheral blood mononuclear cells (peripheral blood draws or leukapheresis)
for use in evaluating allogeneic graft versus host and graft-versus-tumor effects.
The primary objective is to provide a mechanism for collection, tracking, storing,
dispensing, analyzing and disposing of these laboratory research samples from patients and
HLA matched donors.
There is no primary endpoint.
Richard W Childs, M.D.
National Heart, Lung, and Blood Institute (NHLBI)
United States: Federal Government
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Bethesda, Maryland 20892|